LLY looks strong and is consolidating before another move; the host thinks it can keep pushing into end of week.

LLY broke out impulsively after four months of sideways action, mean-reverted and has consolidated near the top for about a week and a half, looking ready to rumble and probably break to a new high this week. He notes it sometimes sweeps a side before breaking out the following week, and that healthcare names are only a 50/50 to keep moving if money rotates back into tech.

After a four-month base, an impulsive breakout and a sideways digestion, Eli Lilly looks ready to break up to a new high this week.

LLY broke out impulsively after four months of sideways action, mean-reverted and has consolidated near the top for about a week and a half, looking ready to rumble and probably break to a new high this week. He notes it sometimes sweeps a side before breaking out the following week, and that healthcare names are only a 50/50 to keep moving if money rotates back into tech.

After a four-month base, an impulsive breakout and a sideways digestion, Eli Lilly looks ready to break up to a new high this week.

At 65x free cash flow and a 39 forward PE, Lilly's premium is hard to justify even with GLP-1 drugs; he's waiting a lot longer before getting involved.

The host owns Eli Lilly and has been buying since around $1,090–$1,100, holding through today's drop.

He currently has no plans to invest in Eli Lilly, grouping it among names he researched but decided against.

The host includes the company in the Rule of 40 group and says these businesses have very strong revenue growth and margins and are moving in the right direction, but he gives no price direction.